‘Don’t Make Promises Until You Have The Data’: FDA Gamble On Speeding Up COVID Vax In Kids Flops
Executive Summary
FDA praised for pulling back on plans to host 15 February advisory committee review of Pfizer’s COVID-19 vaccine in children but faulted, along with other parts of US government, for raising expectations this month that the vaccine might be available for this population imminently.
You may also be interested in...
Vaccine Irony: COVID Complicates Review, Uptake Of New RSV Vaccines
COVID vaccines saved the world and then became a liability. US FDA vaccine advisors cited COVID experience as they urge agency to slow down on approval of new RSV vaccines, due to worries of declining public vaccine confidence and coadministration complications.
Overhyped? White House COVID Coordinator's Claims About New Boosters Go Beyond Data
Ashish Jha made promises about the upcoming bivalent COVID-19 boosters that neither he nor the companies are likely going to be able to keep when the rollout begins.
COVID-19 Vaccines In Five And Younger Could Get Earlier FDA Advisory Committee Review
Peter Marks says agency will proceed to meeting once Pfizer and/or Moderna complete their submissions and that the two may be considered at the same VRBPAC panel. FDA's effectiveness standard has not changed, CBER director says, but acknowledges that vaccines might be a little less effective than 50% in subpopulations.